Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Depression
Interventions: Placebo, Citalopram, Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Asthma
Interventions: Hudson RCI® nebulizer, NebuTech® HDN® nebulizer, Albuterol; Device · Drug
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 3 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Obesity
Interventions: Alternate day fasting; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiac Arrest
Interventions: RUSH Exam; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Streptococcus Infection, Pregnancy
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 358 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2605541, Human Insulin NPH, Oral Antihyperglycemic Medications (OAM); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 20
States / cities: Tempe, Arizona • Concord, California • Fresno, California + 17 more

Conditions: High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
Interventions: Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally; Diagnostic Test · Genetic
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Time Restricted Eating, Diet, Mediterranean
Interventions: Time restricted eating, Mediterranean diet; Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Dyslipidemia
Interventions: CAT 2003, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Nikkomycin Z; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 40 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy Volunteers
Interventions: Glasdegib, High Fat, High Calorie Meal, Rabeprazole; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Myeloma
Interventions: Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 28
States / cities: Alabaster, Alabama • Surprise, Arizona • Berkeley, California + 25 more

Conditions: Lung Cancer, Oligometastatic Lung Tumor
Interventions: One fraction stereotactic body radiotherapy, HyperSight, Ethos; Radiation · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Coronary Artery Disease
Interventions: RXi System, Pressure Wire; Device
Lead sponsor: Acist Medical Systems; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: La Jolla, California • Long Beach, California • Stanford, California + 8 more

Conditions: Migraine Disorders
Interventions: Placebo, Combination Product (sumatriptan succinate/naproxen sodium); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 28
States / cities: Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more

Conditions: HER2-positive Breast Cancer, Advanced Breast Cancer
Interventions: Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Phoenix, Arizona • Miami, Florida • Boston, Massachusetts

Conditions: Vestibular Disorder, Hearing Loss, Sensorineural
Interventions: Dynamic Visual Acuity, Reading Outcomes, Static Visual Acuity; Behavioral
Lead sponsor: Father Flanagan's Boys' Home; Other
Eligibility: 7 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 58
States / cities: Huntsville, Alabama • Vestavia Hills, Alabama • Anaheim, California + 49 more

Conditions: Healthy
Interventions: Rho-11, aspirin 325mg; Drug
Lead sponsor: Rhoshan Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Familial Chylomicronemia Syndrome (FCS)
Interventions: LCQ908, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seatlle, Washington

Conditions: Diabetes Mellitus, Type 1
Interventions: Fiasp, Novolog; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Renal Impairment, Healthy Volunteers
Interventions: Bocidelpar; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Anniston, Alabama • Rialto, California • Miami, Florida + 1 more

Conditions: Nonmelanoma Skin Cancer
Interventions: Electronic Brachytherapy; Procedure
Lead sponsor: Xoft, Inc.; Industry
Eligibility: 41 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Los Gatos, California • San Diego, California • Las Vegas, Nevada

Search by objective public record fields.

Neuroimaging Predictors of Antidepressant Treatment Outcome

Comparison of Nebulizers in ED in Pediatric Asthma Patients

Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions

Alternate Day Fasting Combined With a High Protein Background Diet

RHAPSody: Diagnostic Utility of RUSH Following ROSC

Rapid Diagnostic Test for Detection of Group B Streptococcus in Pregnancy

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

Healthy Lifestyles for Bipolar Disorder

A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003

Comparison of Nikkomycin Z Bioavailability Under Fed and Fasting Conditions

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors

Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

Reading Outcomes in Children With Vestibular Loss

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.